Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
4,766
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
stocks
Paying more for new customers is a troubling sign for ASX share
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,133.30 | 31.50 | -0.34% |
| CAC 40 | 8,167.73 | 63.89 | 0.79% |
| DAX 40 | 24,205.36 | 414.71 | 1.74% |
| Dow JONES (US) | 48,739.41 | 238.14 | 0.49% |
| FTSE 100 | 10,567.65 | 83.52 | 0.80% |
| HKSE | 25,677.40 | 427.92 | 1.69% |
| NASDAQ | 22,807.48 | 290.79 | 1.29% |
| Nikkei 225 | 55,713.27 | 1,467.73 | 2.71% |
| NZX 50 Index | 13,603.47 | 72.35 | 0.53% |
| S&P 500 | 6,869.50 | 52.87 | 0.78% |
| S&P/ASX 200 | 8,910.10 | 33.30 | -0.37% |
| SSE Composite Index | 4,114.17 | 31.70 | 0.78% |